INVO Fertility, Inc.
IVF
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.8M
$0.99
▲ +0.16%
P/E
—
Mkt Cap
$1.8M
52-Wk Range
$0.90–$84.40
52-Week Range
$0.90 - $84.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 97.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary fertility device technology and innovation
- Established revenue-generating fertility business providing cash flow stability
- Diversified pipeline reducing single-product dependency
- Specialized expertise in underserved medical markets
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Rising global fertility treatment demand and market expansion
Value
Valuation data unavailable
Momentum
Falling
-24.2% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IVF right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 23, 2026
AUG 14, 2026
Reported EPS of $0.35 vs -$0.70 consensus (+150.0% surprise). Revenue of $2.2M vs $2.4M expected (-9.2%).
EPS surprise · last 4Q
1 of 2 beats
Estimate
Actual
Q3 26
+150.0%
Q2 26
-22.9%
Revenue trend · last 8Q
—
—
+22%
+4%
+1%
+23%
+20%
+17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q1 26
Q2 26
$1.8M
$1.4M
$1.7M
$1.6M
$1.9M
$1.8M
$2.0M
$2.2M
Margins · last 8Q
Gross
28.4%
Operating
-59.3%
Profit
40.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How IVF stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related